Analysis Of Income And Expense [Abstract]

Oxford Biomedica PLC - Filing #5242757

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	—	139, 989 GBP	—	—	—	—	—	—	—	—	—	—	—	—	142,797,000 GBP	—
Material income and expense [abstract]
Research and development expense	—	—	—	60,937,000 GBP	—	—	—	—	—	—	—	—	—	—	—	—	40,189,000 GBP	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	– GBP	7 ,825 GBP	– GBP	10,575,000 GBP	– GBP	– GBP	2,750,000 GBP	7 ,825 GBP	– GBP	—	—	—	—	—	—	—	– GBP	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	– GBP	31,332,000 GBP	– GBP	34,584,000 GBP	– GBP	39,157,000 GBP	3,252,000 GBP	7 ,825 GBP	– GBP	– GBP	– GBP	– GBP	– GBP	– GBP	– GBP	19, 011 GBP	19 ,011 GBP	19,011,000 GBP
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	—	—	31,332,000 GBP	—	—	—	—	—	—	—	—	—	—	—	—	19, 011 GBP	—
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests	—	—	—	3,252,000 GBP	—	—	—	—	—	—	—	—	—	—	—	—	– GBP	—